计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| R414071-5mg |
5mg |
现货 ![]() |
| |
| R414071-10mg |
10mg |
现货 ![]() |
| |
| R414071-25mg |
25mg |
现货 ![]() |
| |
| R414071-50mg |
50mg |
现货 ![]() |
| |
| R414071-100mg |
100mg |
现货 ![]() |
| |
| R414071-250mg |
250mg |
现货 ![]() |
| |
| R414071-500mg |
500mg |
现货 ![]() |
|
| 英文别名 | SCHEMBL16946804 | NSC800522 | NSC-800522 | (2R)-2-[[6-(benzylamino)-9-propan-2-yl-purin-2-yl]amino]butan-1-ol | (7S,13R)-11-fluoro-6,7,13,14-tetrahydro-7,13-dimethyl-1,15-etheno-1H-pyrazolo[4,3-f][1,4,8,10]benzoxatriazacyclotridecin-4(5H)-one | E102 | BDB |
|---|---|
| 规格或纯度 | Moligand™, ≥98% |
| 英文名称 | Repotrectinib (TPX-0005) |
| 生化机理 | Repotrectinib(TPX-0005)是一种新型 ALK/ROS1/TRK 抑制剂,对 WT ALK 的 IC50 值为 1.01 nM,对 ALK(G1202R) 的 IC50 值为 1.26 nM,对 ALK(L1196M) 的 IC50 值为 1.08 nM;同时也是一种强效的 SRC 抑制剂(IC50 5.3 nM)。 |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 抑制剂 |
| 作用机制 | ALK 受体酪氨酸激酶抑制剂;c-ros 致癌基因 1;受体酪氨酸激酶抑制剂;Janus 激酶 2 抑制剂;神经营养受体酪氨酸激酶 1 抑制剂;神经营养受体酪氨酸激酶 2 抑制剂;神经营养受体酪氨酸激酶 3 抑制剂 |
| 产品介绍 |
Information Repotrectinib (TPX-0005) Repotrectinib (TPX-0005) is a novel ALK/ROS1/TRK inhibitor with the IC50 values of 1.01 nM for WT ALK, 1.26 nM for ALK(G1202R), and 1.08 nM for ALK(L1196M); also a potent SRC inhibitor (IC50 5.3 nM). Targets ROS1 ; Trk receptor ; WT ALK (Cell-free assay); ALK(L1196M) (Cell-free assay); ALK(G1202R) (Cell-free assay) 27980,; 1.01 nM; 1.08 nM; 1.26 nM In vitro TPX-0005 is an orally available and potent ATP-competitive inhibitor against ALK, ROS1, TRKA, TRKB and TRKC recombinant kinases and their corresponding clinical resistant mutants. TPX-0005 demonstrates potent anti-proliferative activity in the range of sub-nanomolar to low nanomolar in a number of human cancer cell lines and engineered stable cell lines expressing the targeted oncogenes or their solvent front mutants, accompanied by inhibition of target phosphorylation and concomitant inactivation of downstream effectors such as ERK, AKT and STAT3. TPX-0005 inhibits H2228 cell migration in a wound healing assay with similar activity to saracatinib. TPX-0005 is able to not only inhibit the wild-type and a broad spectrum of mutant ALKs, but also overcome primary resistance and suppress metastatic features by inhibiting SRC. In vivo In patient derived xenograft tumor models, TPX-0005 treatment results in significant regression of tumors harboring the oncogenic ALK, ROS1 and TRKC fusions. Moreover, in a series of mouse xenograft tumor models, TPX-0005 exhibits marked anti-tumor activity not only in tumors harboring the wildtype oncogenic targets but also in tumors harboring the oncogenes with the solvent front mutations via inhibition of the target phosphorylation. |
| 纯度 | ≥98% |
| ALogP | 2.005 |
|---|---|
| HBD Count | 2 |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| PubChem SID | 504773395 |
|---|---|
| 分子类型 | 小分子 |
| IIUPAC Name | (3R,11S)-6-fluoro-3,11-dimethyl-10-oxa-2,13,17,18,21-pentazatetracyclo[13.5.2.04,9.018,22]docosa-1(21),4(9),5,7,15(22),16,19-heptaen-14-one |
| INCHI | 1S/C18H18FN5O2/c1-10-8-20-18(25)14-9-21-24-6-5-16(23-17(14)24)22-11(2)13-7-12(19)3-4-15(13)26-10/h3-7,9-11H,8H2,1-2H3,(H,20,25)(H,22,23)/t10-,11+/m0/s1 |
| InChi Key | FIKPXCOQUIZNHB-WDEREUQCSA-N |
| Smiles | CC1CNC(=O)C2=C3N=C(C=CN3N=C2)NC(C4=C(O1)C=CC(=C4)F)C |
| Isomeric SMILES | C[C@H]1CNC(=O)C2=C3N=C(C=CN3N=C2)N[C@@H](C4=C(O1)C=CC(=C4)F)C |
| PubChem CID | 135565923 |
| 分子量 | 355.37 |
| 溶解性 | Solubility (25°C) In vitro DMSO: 71 mg/mL (199.79 mM); Ethanol: 10 mg/mL (28.13 mM); Water: Insoluble; |
|---|---|
| DMSO(mg / mL) Max Solubility | 70 |
| DMSO(mM) Max Solubility | 196.9777978 |
| Water(mg / mL) Max Solubility | <1 |
| 分子量 | 355.400 g/mol |
| XLogP3 | 2.100 |
| 氢键供体数Hydrogen Bond Donor Count | 2 |
| 氢键受体数Hydrogen Bond Acceptor Count | 6 |
| 可旋转键计数Rotatable Bond Count | 0 |
| 精确质量Exact Mass | 355.144 Da |
| 单同位素质量Monoisotopic Mass | 355.144 Da |
| 拓扑极表面积Topological Polar Surface Area | 80.600 Ų |
| 重原子数Heavy Atom Count | 26 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 524.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 2 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
| 象形图 | GHS07 |
|---|---|
| 信号词 | 警告 |
| 危险声明 |
H302: 吞食有害 H315: 引起皮肤刺激 H319: 引起严重眼睛刺激 H335: 可能引起呼吸道刺激 |
| 预防措施声明 |
P261: 避免吸入灰尘/烟雾/气体/雾/蒸汽/喷雾 P305+P351+P338: 如进入眼睛:用水小心冲洗几分钟。如戴隐形眼镜并可方便地取出,取出隐形眼镜。继续冲洗。 |
| 1. Drilon A, Ou SI, Cho BC, Kim DW, Lee J, Lin JJ, Zhu VW, Ahn MJ, Camidge DR, Nguyen J et al.. (2018) Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations.. Cancer Discov, 8 (10): (1227-1236). [PMID:30093503] |